Cargando…
One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial
There has been no previous prospective study evaluating dual antiplatelet therapy (DAPT) duration shorter than 6 months after cobalt-chromium everolimus-eluting stent (CoCr-EES) implantation. STOPDAPT trial is a prospective multi-center single-arm study evaluating 3-month DAPT duration after CoCr-EE...
Autores principales: | Natsuaki, Masahiro, Morimoto, Takeshi, Yamamoto, Erika, Shiomi, Hiroki, Furukawa, Yutaka, Abe, Mitsuru, Nakao, Koichi, Ishikawa, Tetsuya, Kawai, Kazuya, Yunoki, Kei, Shimizu, Shogo, Akao, Masaharu, Miki, Shinji, Yamamoto, Masashi, Okada, Hisayuki, Hoshino, Kozo, Kadota, Kazushige, Morino, Yoshihiro, Igarashi, Keiichi, Tanabe, Kengo, Kozuma, Ken, Kimura, Takeshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923071/ https://www.ncbi.nlm.nih.gov/pubmed/26518420 http://dx.doi.org/10.1007/s12928-015-0366-9 |
Ejemplares similares
-
Very Late Pathological Responses to Cobalt–Chromium Everolimus‐Eluting, Stainless Steel Sirolimus‐Eluting, and Cobalt–Chromium Bare Metal Stents in Humans
por: Mori, Hiroyoshi, et al.
Publicado: (2017) -
One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation
por: Natsuaki, Masahiro, et al.
Publicado: (2020) -
Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis
por: Valgimigli, Marco, et al.
Publicado: (2014) -
A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease
por: Bennett, Johan, et al.
Publicado: (2013) -
One‐Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus‐Eluting Stents in High Bleeding Risk Patients
por: Pivato, Carlo A., et al.
Publicado: (2022)